Strategies for Hepatitis C Testing and Treatment in Aboriginal Communities That Lead to Elimination

UnknownOBSERVATIONAL
Enrollment

600

Participants

Timeline

Start Date

May 28, 2019

Primary Completion Date

August 31, 2022

Study Completion Date

August 31, 2022

Conditions
Hepatitis CHepatitisLiver DiseasesHepatitis, Viral, HumanRNA Virus InfectionsDigestive System Diseases
Interventions
DEVICE

Fingerstick GeneXpert HCV RNA quantitative assay

All participants at risk of HCV infection will receive HCV RNA testing using the GeneXpert finger-stick point-of-care HCV quantitative assay 6 monthly

DRUG

sofosbuvir/velpatesvir

Participants with active HCV infection will be offered treatment with one of two pan-genotypic regimens available in Australia

DRUG

glecaprevir/pibrentasvir

Participants with active HCV infection will be offered treatment with one of two pan-genotypic regimens available in Australia

Trial Locations (4)

2343

RECRUITING

Walhallow Aboriginal Corporation, Quirindi

2480

RECRUITING

Jullums Lismore Aboriginal Medical Service, Lismore

5290

RECRUITING

Pangula Mannamurna Aboriginal Corporation, Mount Gambier

5606

RECRUITING

Port Lincoln Aboriginal Health Service, Port Lincoln

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

South Australian Health and Medical Research Institute

OTHER

collaborator

Flinders University

OTHER

lead

Kirby Institute

OTHER_GOV